Family · Pharmaceutical analytical standards
Enzalutamide
A second-generation non-steroidal antiandrogen: it blocks the androgen receptor at three points, namely hormone binding, entry into the nucleus and binding to DNA. Approved in the United States in 2012 for advanced prostate cancer. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was born at the University of California, Los Angeles (UCLA), from a collaboration between oncologist Charles Sawyers and chemist Michael Jung.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
